Abstract
Objective: The aim of this study was to evaluate the clinical efficacy of elemene intrapleural injection in the treatment of lung cancer with malignant pleural effusion by meta-analysis. Materials and Methods: PubMed (1960-2014.4), EMBASE (1980-2014.4) and CNKI (1979-2014.4) data bases were searched to identify the randomized controlled trials about elemene intrapleural injection in the treatment of malignant pleural effusion caused by lung cancer. The relativel risk (RR) was used to evaluated the the clinical efficacy of elemene intrapleural injection in the treatment of pleural effusion compared to other drugs. Results: A total of 1298 subjects with 14 studies were finally included in this meta-analysis. Meta-analysis showed that the objective response rate (ORR) in elemene group was much higher than that in other drugs group (RR =1.20, 95% CI:1.05-1.37, P = 0.008). We performed the sub-groups analysis according to the drugs used in the control group. And the subgroup analyzed demonstrated that the ORR in elemene group was higher than that in Cisplatin (DDP) and high sugar group with statistical difference (P < 0.05). But no statistical difference was found in the bleomycin and interleukin-2 [IL-2] subgroups (P > 0.05). Conclusion: High clinical efficacy of elemene was found in the treatment malignant pleural effusion in patients with lung cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer